0001179110-18-011797.txt : 20181002
0001179110-18-011797.hdr.sgml : 20181002
20181002073239
ACCESSION NUMBER: 0001179110-18-011797
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181001
FILED AS OF DATE: 20181002
DATE AS OF CHANGE: 20181002
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McMahon Gerald PhD
CENTRAL INDEX KEY: 0001290747
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 181099312
MAIL ADDRESS:
STREET 1: 300 ELLIOTT AVENUE WEST
STREET 2: SUITE 500
CITY: SEATTLE
STATE: WA
ZIP: 98119-4114
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
FORM 4 -
X0306
4
2018-10-01
0
0000744218
Celldex Therapeutics, Inc.
CLDX
0001290747
McMahon Gerald PhD
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
1
0
0
0
Common Stock, par value $0.001
2018-10-01
4
F
0
2888
.451
D
186409
D
On November 28, 2016, in connection with the Reporting Person's employment severance agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal installments through December 2018.
Pursuant to the Severance Agreement, on October 1, 2018, the Issuer issued 5,466 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 2,888 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.
/s/ Samuel B. Martin, attorney-in-fact for Gerald McMahon
2018-10-02